Dalvir Gill has more than 30 years of drug development & leadership experience. Prior to his appointment as CEO of TransCelerate, he was the President of a major international CRO. Dr. Gill earned his BSc from the University of Hertfordshire and his PhD from the Royal Free Hospital School of Medicine, University of London. He also holds a diploma in the Health Economics of Pharmaceuticals from the Stockholm School of Economics. Dr. Gill has presented his research and spoken at numerous conferences and has authored more than 30 scientific publications. He also is an elected fellow of the Royal Society of Medicine. Dr. Gill serves as the Chief Executive Officer of TransCelerate BioPharma Inc. and its subsidiary, BioCelerate.